Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | KDM6B | O15054 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | KDM5C | P41229 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.45 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20027715 | 0.80 | KDM4E (0.46) | KDM4EKDM6BKDM4AKDM5CKDM4C | |
| SCHEMBL25778937 | 0.79 | CAMKK2 (0.42) | KDM4EKDM6BKDM4AKDM4CTDP1 | |
| SCHEMBL25778930 | 0.79 | DHODH (0.44) | KDM4EKDM6BKDM4AKDM5CKDM4C | |
| SCHEMBL286190 | 0.79 | LMNA (0.49) | KDM4ELMNAGABRA5NPC1TP53 | |
| SCHEMBL1225673 | 0.78 | PTGS2 (0.44) | KDM4EDHODHLMNAPOLBNPC1 | |
| SCHEMBL25778935 | 0.77 | KDM4E (0.42) | KDM4EKDM6BKDM4AKDM4CTDP1 | |
| SCHEMBL29693966 | 0.76 | KDM4E (0.71) | KDM4EKDM6BKDM4AKDM5CKDM4C | |
| SCHEMBL646624 | 0.76 | KDM4E (0.71) | KDM4EKDM6BKDM4AKDM5CKDM4C | |
| SCHEMBL27934992 | 0.76 | PTGS2 (0.43) | KDM4EDHODHLMNAPOLBNPC1 | |
| SCHEMBL1777112 | 0.75 | GABRA5 (0.46) | DHODHNAPRTP4HTMGRM5GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118434-A1 | PESTICIDALLY ACTIVE AMIDE COMPOUNDS | GLOBACHEM NV (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| EP-2231651-B1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-11-21 | — | — | EP | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| EP-2229383-B1 | ISOXAZOLO-PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2427459-B1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2767536-B1 | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2010127974-A1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100256154-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2231651-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-2229383-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| EP-2227467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009071464-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071476-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071477-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | KDM4E 1485/4885KDM6B 1693/4885KDM4A 2331/4885 |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA1 | KDM4E 1917/4885KDM6B 2111/4885KDM4A 2301/4885 |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | KDM4E 3495/4885KDM6B 3700/4885KDM4A 3935/4885 |
| US-20100256154-A1 | ISOXAZOLO-PYRAZINE DERIVATIVES | GABRA5, GRIK5, GABRA4 | KDM4E 1822/4885KDM6B 2664/4885KDM4A 2093/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | KDM4E 3117/4885KDM6B 3542/4885KDM4A 3968/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | KDM4E 3495/4885KDM6B 3700/4885KDM4A 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.